| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 48 | 2024 | 2037 | 3.200 |
Why?
|
| Anti-HIV Agents | 17 | 2024 | 359 | 2.300 |
Why?
|
| Infectious Disease Transmission, Vertical | 15 | 2022 | 260 | 1.450 |
Why?
|
| Pregnancy Complications, Infectious | 12 | 2024 | 500 | 1.080 |
Why?
|
| HIV-1 | 8 | 2022 | 477 | 0.890 |
Why?
|
| Homeless Youth | 4 | 2024 | 13 | 0.870 |
Why?
|
| Drug Resistance, Viral | 3 | 2022 | 56 | 0.860 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2022 | 77 | 0.720 |
Why?
|
| Pre-Exposure Prophylaxis | 4 | 2024 | 54 | 0.660 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2022 | 234 | 0.630 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2022 | 382 | 0.580 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2017 | 462 | 0.560 |
Why?
|
| Risk Reduction Behavior | 2 | 2024 | 148 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 5 | 2022 | 153 | 0.500 |
Why?
|
| Diketopiperazines | 1 | 2024 | 8 | 0.430 |
Why?
|
| Sexual Behavior | 5 | 2024 | 245 | 0.420 |
Why?
|
| Sexual and Gender Minorities | 3 | 2024 | 68 | 0.410 |
Why?
|
| Viral Load | 7 | 2019 | 406 | 0.400 |
Why?
|
| Homosexuality, Male | 4 | 2024 | 63 | 0.390 |
Why?
|
| Granulomatous Disease, Chronic | 5 | 2011 | 70 | 0.350 |
Why?
|
| Adolescent | 32 | 2024 | 20917 | 0.340 |
Why?
|
| Drug Monitoring | 3 | 2019 | 285 | 0.340 |
Why?
|
| HIV Seropositivity | 2 | 2010 | 124 | 0.310 |
Why?
|
| Pregnancy | 18 | 2024 | 7572 | 0.310 |
Why?
|
| Papillomavirus Infections | 3 | 2021 | 389 | 0.280 |
Why?
|
| Medication Adherence | 2 | 2024 | 334 | 0.270 |
Why?
|
| Humans | 61 | 2024 | 131504 | 0.260 |
Why?
|
| Female | 47 | 2024 | 71087 | 0.260 |
Why?
|
| Child | 28 | 2024 | 26239 | 0.250 |
Why?
|
| Young Adult | 15 | 2024 | 10092 | 0.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2004 | 222 | 0.250 |
Why?
|
| Infant, Newborn | 15 | 2024 | 8589 | 0.240 |
Why?
|
| Papillomaviridae | 3 | 2021 | 179 | 0.230 |
Why?
|
| Adult | 25 | 2024 | 31666 | 0.220 |
Why?
|
| Health Personnel | 1 | 2010 | 549 | 0.220 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2024 | 98 | 0.220 |
Why?
|
| Male | 37 | 2024 | 65158 | 0.220 |
Why?
|
| Case Management | 1 | 2024 | 17 | 0.220 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2005 | 33 | 0.220 |
Why?
|
| Severe Combined Immunodeficiency | 3 | 2010 | 106 | 0.220 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 34 | 0.220 |
Why?
|
| Antigens, CD | 2 | 2008 | 418 | 0.210 |
Why?
|
| Text Messaging | 1 | 2024 | 39 | 0.210 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2013 | 132 | 0.210 |
Why?
|
| United States | 13 | 2024 | 11794 | 0.200 |
Why?
|
| Transgender Persons | 1 | 2024 | 68 | 0.200 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 1169 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2017 | 496 | 0.200 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2022 | 228 | 0.190 |
Why?
|
| Immunologic Tests | 1 | 2002 | 17 | 0.190 |
Why?
|
| Vaccines, Attenuated | 1 | 2022 | 174 | 0.190 |
Why?
|
| Pregnancy Outcome | 2 | 2024 | 630 | 0.190 |
Why?
|
| Atazanavir Sulfate | 1 | 2022 | 6 | 0.190 |
Why?
|
| Anal Canal | 2 | 2021 | 86 | 0.180 |
Why?
|
| HIV Protease Inhibitors | 1 | 2022 | 44 | 0.180 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2022 | 153 | 0.180 |
Why?
|
| Cough | 1 | 2022 | 99 | 0.180 |
Why?
|
| HIV Long-Term Survivors | 1 | 2001 | 5 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2013 | 260 | 0.180 |
Why?
|
| Anus Neoplasms | 1 | 2021 | 43 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 46 | 0.170 |
Why?
|
| Prevalence | 8 | 2024 | 2692 | 0.170 |
Why?
|
| Infant | 19 | 2016 | 13300 | 0.170 |
Why?
|
| Cohort Studies | 11 | 2024 | 5120 | 0.160 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2002 | 210 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 199 | 0.160 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 111 | 0.160 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2017 | 232 | 0.160 |
Why?
|
| Postpartum Period | 4 | 2022 | 235 | 0.150 |
Why?
|
| Preventive Health Services | 1 | 2019 | 58 | 0.150 |
Why?
|
| Genitalia, Male | 1 | 2019 | 35 | 0.150 |
Why?
|
| Pyridones | 2 | 2024 | 148 | 0.150 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 517 | 0.150 |
Why?
|
| Mothers | 1 | 2022 | 371 | 0.140 |
Why?
|
| Chemoprevention | 2 | 2015 | 51 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2019 | 353 | 0.140 |
Why?
|
| Mouth | 1 | 2019 | 66 | 0.140 |
Why?
|
| Child, Preschool | 16 | 2022 | 15047 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 77 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 344 | 0.120 |
Why?
|
| Esophageal Diseases | 1 | 1996 | 33 | 0.120 |
Why?
|
| Eosinophils | 1 | 2017 | 126 | 0.120 |
Why?
|
| Methylprednisolone | 1 | 1996 | 97 | 0.120 |
Why?
|
| Minors | 1 | 2015 | 4 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 2024 | 440 | 0.120 |
Why?
|
| Prednisone | 1 | 1996 | 244 | 0.120 |
Why?
|
| Chickenpox Vaccine | 1 | 2015 | 14 | 0.120 |
Why?
|
| Parental Consent | 1 | 2015 | 22 | 0.120 |
Why?
|
| Chickenpox | 1 | 2015 | 22 | 0.120 |
Why?
|
| Genotype | 1 | 2022 | 2655 | 0.120 |
Why?
|
| Contraceptive Agents | 1 | 2015 | 13 | 0.120 |
Why?
|
| Contraception Behavior | 1 | 2015 | 29 | 0.110 |
Why?
|
| Research Subjects | 1 | 2015 | 53 | 0.110 |
Why?
|
| Prospective Studies | 7 | 2022 | 6485 | 0.110 |
Why?
|
| Asthma | 2 | 2017 | 927 | 0.110 |
Why?
|
| Abortion, Induced | 1 | 2015 | 85 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 506 | 0.110 |
Why?
|
| Rilpivirine | 1 | 2024 | 5 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 1996 | 350 | 0.100 |
Why?
|
| Aftercare | 1 | 2015 | 154 | 0.100 |
Why?
|
| Health Policy | 1 | 2015 | 227 | 0.100 |
Why?
|
| Dangerous Behavior | 1 | 2012 | 11 | 0.100 |
Why?
|
| Global Health | 1 | 2018 | 632 | 0.100 |
Why?
|
| Food Supply | 1 | 2013 | 91 | 0.090 |
Why?
|
| Cobicistat | 2 | 2022 | 2 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2011 | 1263 | 0.090 |
Why?
|
| Child Behavior Disorders | 1 | 2012 | 70 | 0.090 |
Why?
|
| Unrelated Donors | 1 | 2011 | 71 | 0.090 |
Why?
|
| Incidence | 6 | 2017 | 3344 | 0.090 |
Why?
|
| HIV | 2 | 2022 | 179 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1139 | 0.080 |
Why?
|
| RNA, Viral | 3 | 2010 | 513 | 0.080 |
Why?
|
| Malawi | 3 | 2017 | 339 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 501 | 0.080 |
Why?
|
| Rotavirus Vaccines | 1 | 2010 | 60 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2010 | 93 | 0.080 |
Why?
|
| Osteomyelitis | 2 | 2007 | 212 | 0.080 |
Why?
|
| Truth Disclosure | 1 | 2010 | 108 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2008 | 32 | 0.070 |
Why?
|
| Sleep | 1 | 2012 | 373 | 0.070 |
Why?
|
| Lymphocyte Depletion | 1 | 2008 | 123 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 1516 | 0.070 |
Why?
|
| Disease Progression | 4 | 2006 | 2205 | 0.070 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 99 | 0.070 |
Why?
|
| Herpesvirus 2, Human | 1 | 2008 | 14 | 0.070 |
Why?
|
| Failure to Thrive | 2 | 2010 | 88 | 0.070 |
Why?
|
| Herpes Genitalis | 1 | 2008 | 10 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2011 | 502 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2012 | 565 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 329 | 0.070 |
Why?
|
| Basidiomycota | 1 | 2007 | 11 | 0.070 |
Why?
|
| Rotavirus Infections | 1 | 2010 | 281 | 0.070 |
Why?
|
| Vaccination | 2 | 2024 | 1040 | 0.070 |
Why?
|
| Rotavirus | 1 | 2010 | 366 | 0.070 |
Why?
|
| Placenta | 2 | 2022 | 529 | 0.060 |
Why?
|
| Central Nervous System | 1 | 2009 | 286 | 0.060 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2007 | 98 | 0.060 |
Why?
|
| Mycoses | 1 | 2007 | 110 | 0.060 |
Why?
|
| Cytokines | 1 | 2012 | 1347 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 590 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 3834 | 0.060 |
Why?
|
| Condoms | 1 | 2024 | 50 | 0.050 |
Why?
|
| Growth | 1 | 2005 | 92 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 46 | 0.050 |
Why?
|
| Amides | 1 | 2024 | 91 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2005 | 336 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2024 | 98 | 0.050 |
Why?
|
| Morbidity | 1 | 2005 | 258 | 0.050 |
Why?
|
| Executive Function | 2 | 2017 | 136 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 63 | 0.050 |
Why?
|
| ROC Curve | 1 | 2005 | 615 | 0.050 |
Why?
|
| Women's Health | 1 | 2004 | 143 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 769 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 680 | 0.050 |
Why?
|
| Piperazines | 1 | 2024 | 272 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2024 | 242 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1008 | 0.050 |
Why?
|
| Tenofovir | 1 | 2022 | 25 | 0.050 |
Why?
|
| Medication Therapy Management | 1 | 2022 | 22 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 95 | 0.040 |
Why?
|
| NAD+ Nucleosidase | 1 | 2001 | 2 | 0.040 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2001 | 4 | 0.040 |
Why?
|
| CD57 Antigens | 1 | 2001 | 5 | 0.040 |
Why?
|
| Darunavir | 1 | 2021 | 3 | 0.040 |
Why?
|
| Alanine | 1 | 2022 | 163 | 0.040 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2001 | 18 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1487 | 0.040 |
Why?
|
| Adenine | 1 | 2022 | 124 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2001 | 70 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 63 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2001 | 75 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 1168 | 0.040 |
Why?
|
| Income | 1 | 2022 | 135 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2002 | 185 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2004 | 290 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 703 | 0.040 |
Why?
|
| Growth Disorders | 1 | 2022 | 184 | 0.040 |
Why?
|
| Graft vs Host Disease | 3 | 2011 | 681 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2001 | 159 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 1831 | 0.040 |
Why?
|
| Gestational Age | 1 | 2024 | 1221 | 0.040 |
Why?
|
| Patient Selection | 1 | 2024 | 723 | 0.040 |
Why?
|
| Premature Birth | 1 | 2024 | 415 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2005 | 493 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2002 | 542 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2015 | 773 | 0.040 |
Why?
|
| Poisson Distribution | 2 | 2013 | 50 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2143 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1788 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2022 | 12936 | 0.040 |
Why?
|
| Immunoglobulin E | 2 | 2017 | 225 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 11 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 50 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2005 | 856 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 421 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 282 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2019 | 209 | 0.030 |
Why?
|
| Counseling | 1 | 2019 | 237 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 69 | 0.030 |
Why?
|
| International Cooperation | 1 | 2018 | 161 | 0.030 |
Why?
|
| Stereotyping | 1 | 2017 | 19 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 130 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2010 | 451 | 0.030 |
Why?
|
| Time Factors | 3 | 2017 | 6273 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2022 | 812 | 0.030 |
Why?
|
| Mycobacterium avium Complex | 1 | 1996 | 20 | 0.030 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1996 | 24 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 220 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1996 | 242 | 0.030 |
Why?
|
| Disclosure | 1 | 2017 | 149 | 0.030 |
Why?
|
| Hospitalization | 1 | 2005 | 1939 | 0.030 |
Why?
|
| State Government | 1 | 2015 | 30 | 0.030 |
Why?
|
| Abortion Applicants | 1 | 2015 | 2 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2017 | 149 | 0.030 |
Why?
|
| Ghana | 1 | 2015 | 21 | 0.030 |
Why?
|
| Pregnancy, Unplanned | 1 | 2015 | 8 | 0.030 |
Why?
|
| Linear Models | 2 | 2013 | 695 | 0.030 |
Why?
|
| Risk Factors | 4 | 2013 | 10952 | 0.030 |
Why?
|
| Family Planning Services | 1 | 2015 | 39 | 0.030 |
Why?
|
| Prognosis | 1 | 2005 | 4951 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1685 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 167 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 236 | 0.030 |
Why?
|
| Colitis | 1 | 1996 | 159 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1996 | 225 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 1994 | 43 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1996 | 705 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1994 | 46 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1994 | 90 | 0.030 |
Why?
|
| Spinal Diseases | 1 | 1994 | 47 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 558 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 825 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 695 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 39 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 1338 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2013 | 101 | 0.020 |
Why?
|
| Age Factors | 1 | 2019 | 2870 | 0.020 |
Why?
|
| Unsafe Sex | 1 | 2012 | 23 | 0.020 |
Why?
|
| Lymphocyte Count | 2 | 2006 | 120 | 0.020 |
Why?
|
| Community Health Workers | 1 | 2013 | 82 | 0.020 |
Why?
|
| Sibling Relations | 1 | 2011 | 12 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2015 | 17648 | 0.020 |
Why?
|
| Caregivers | 1 | 2017 | 583 | 0.020 |
Why?
|
| Quality of Life | 2 | 2011 | 2107 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 281 | 0.020 |
Why?
|
| Diarrhea, Infantile | 1 | 2010 | 31 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 40 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2010 | 75 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 670 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 409 | 0.020 |
Why?
|
| Mental Processes | 1 | 2009 | 38 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 4517 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 210 | 0.020 |
Why?
|
| Memory | 1 | 2012 | 358 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1450 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5277 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 595 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 995 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 794 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 236 | 0.020 |
Why?
|
| Sex Factors | 2 | 2006 | 1345 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 178 | 0.020 |
Why?
|
| Sacrum | 1 | 2007 | 28 | 0.020 |
Why?
|
| Voriconazole | 1 | 2007 | 30 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2007 | 35 | 0.020 |
Why?
|
| Perinatal Care | 1 | 2008 | 67 | 0.020 |
Why?
|
| HMGB1 Protein | 1 | 2007 | 28 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2007 | 49 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2008 | 218 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 28839 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1236 | 0.020 |
Why?
|
| Echinocandins | 1 | 2007 | 42 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 4037 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1078 | 0.020 |
Why?
|
| Graft Survival | 1 | 2008 | 465 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 909 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 810 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 38 | 0.020 |
Why?
|
| Triazoles | 1 | 2007 | 143 | 0.020 |
Why?
|
| Feces | 1 | 2010 | 725 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 298 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2008 | 560 | 0.010 |
Why?
|
| Texas | 1 | 2013 | 3614 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1745 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2007 | 443 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 2004 | 108 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2149 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1590 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1404 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 145 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2004 | 435 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2002 | 238 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 186 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2002 | 156 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 926 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1522 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3452 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1910 | 0.010 |
Why?
|
| Respiratory Hypersensitivity | 1 | 1997 | 55 | 0.010 |
Why?
|
| Eosinophilia | 1 | 1997 | 109 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 2116 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 1997 | 231 | 0.010 |
Why?
|
| Itraconazole | 1 | 1994 | 24 | 0.010 |
Why?
|
| Granulocytes | 1 | 1994 | 69 | 0.010 |
Why?
|
| Survivors | 1 | 1995 | 354 | 0.010 |
Why?
|